arrow
F

Frédéric Guyon

Aristotle University of Thessaloniki
H指数:33
被引数:3,999

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database

无铂间期(PFI)及维持治疗在复发性卵巢癌中的作用:解释生存率的法国真实世界ESME卵巢数据库分析

2025-08-070
PRE
Deep Learning Can Accurately Predict the Prognosis of Gynecologic Smooth Muscle Tumors of Uncertain Malignant Potential: A Multicenter Pilot Study

深度学习能够准确预测妇科平滑肌肿瘤不确定恶性潜能的预后:一项多中心试点研究

2025-06-300
PRE
Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer (CHIPOR): A Randomized, Open-Label, Phase 3 Trial Editorial comment

腹腔热灌注化疗治疗复发性卵巢癌(CHIPOR):一项随机、开放标签、III期试验编辑评论

2025-05-010
PRE
POLE Mutation Rates And P53 Abnormal Rates And Correlation With Histopathological Parameters In Endometrial Cancer Patients: Prospective Observational Cohort

POLE突变率、P53异常率及其与子宫内膜癌患者组织病理学参数的相关性:前瞻性观察性队列研究

2025-02-010
PRE
Surgical Outcomes In Low-Grade Serous Ovarian Cancer: Comparing Primary Debulking Surgery With Neoadjuvant Chemotherapy

低级别浆液性卵巢癌的手术结果:比较初始肿瘤细胞减灭术与术前新辅助化疗

2025-02-010
PRE
Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation

具有奇异核的平滑肌瘤和富马酸水合酶缺陷型平滑肌瘤的基因组图谱分析: array-cgh解释的优势,劣势和局限性

2024-03-134
PRE
Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial
2024-01-010
OAAI
Management of Endometrial Cancer: French Society of Onco-Gynecology's Evaluation through a Delphi Survey
2022-11-152
OAAI
Clinical Trial
2021-05-0180
PREAI
Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
2021-01-017
OAAI
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome (vol 43, pg 253, 2019)
2020-07-012
OAAI
The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas
2020-02-1415
OAAI